Cross-sectional assessments of participants’ characteristics and loss to follow-up in the first Opioid Substitution Therapy Pilot Program in Kabul, Afghanistan

Harm Reduction Journal

Gilbert Burnham⁴  Feda M Paikan⁵  Ernst Wisse²  Senop Tschakarjan³  Ahmad Farhad³  Cyrus Engineer⁹  Iliassou Mfochive⁴  Mark Berry¹  Itziar Familiar-Lopez⁷  Andrea L Wirtz⁶  Alexander Vu⁸  Horacio Ruiseñor-Escudero⁴ 

[1] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore 21205, MD, USA;Medecins du Monde, 63 rue de Marcadet, Paris 75018, France;Medecins du Monde, Kabul, Afghanistan;Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore 21205, MD, USA;National AIDS Control Program, Kabul, Afghanistan;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Center for Public Health and Human Rights, 615 N Wolfe Street, Baltimore 21205, MD, USA;Department of Psychiatry, Michigan State University, College of Ostheopathic Medicine, 965 E Fee Hall Suite A227, Lansing 48824, MI, USA;Department of Emergency Medicine, Johns Hopkins University, School of Medicine, 5801 Smith Avenue, Suite 3220, Baltimore 21205, MD, USA;Department of Interprofessional Health Studies, Towson University, Baltimore 21252, MD, USA

关键词: Afghanistan;    Injecting drug use;    Methadone;    Heroin;    Opiate substitution therapy;   

Others  :  1224566
DOI  :  10.1186/s12954-015-0062-1

 received in 2015-07-18, accepted in 2015-08-23,  发布年份 2015

【 摘 要 】

Background

Kabul has over 12,000 people who inject drugs (PWID), most of them heroin users, and opioid substitution therapy has recently been introduced as an effective method to reduce opioid use. We aimed to evaluate a pilot Opioid Substitution Therapy Pilot Program (OSTPP) in Kabul, Afghanistan, particularly to (1) describe characteristics of the participants enrolled in the program and (2) identify factors associated with client retention in the OSTPP.

Findings

Two cross-sectional surveys evaluated participants attending the OSTPP at baseline (n = 83) and 18 months after (n = 57). Questionnaires assessed socio-demographic, drug use behavior, and general and mental health factors. After 18 months, 57 participants remained in the OSTPP. Participants lost to follow-up were younger (p < 0.01) and married (p < 0.01) and had no family contact (p < 0.01). Participants at 18 months reported no criminal activity in the last month and only two (3.5 %) reported heroin use in the last month, constituting significant decreases from baseline.

Conclusions

While preliminary results are promising, further evaluation is needed to determine the feasibility of implementing OSTPP in this setting and effectiveness in reducing injection risk behaviors in Afghanistan.

【 授权许可】

   
2015 Ruiseñor-Escudero et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Integrated Biological and Behavioral Survey 2009 (IBBS), Afghanistan. vol. One. Kabul, Afghanistan. 2010.
• [2]World Drug Report 2013. World Health Organization, Geneva, Switzerland; 2013.
• [3]Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. JAIDS. 2010; 55:S10.
• [4]Todd CS, Macdonald D, Khoshnood K, Mansoor GF, Eggerman M, Panter-Brick C. Opiate use, treatment, and harm reduction in Afghanistan: recent changes and future directions. Int J Drug Policy. 2012; 23(5):341-345.
• [5]Des Jarlais DC, Boltaev A, Feelemyer J, Bramson H, Arasteh K, Phillips BW et al.. Gender disparities in HIV infection among persons who inject drugs in central Asia: a systematic review and meta-analysis. Drug Alcohol Depend. 2013; Suppl 1:S7-12.
• [6]Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N et al.. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul. Afghanistan Emerging Infect Dis. 2007; 13(9):1327-1331.
• [7]Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): a national survey of Canadians’ use of alcohol and other drugs: prevalence of use and related harms: Detailed report. Ottawa, Canadian Centre on Substance Abuse; 2005.
• [8]WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users–2012 revision. 2012.
• [9]Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010; 376(9737):285-301.
• [10]MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345.
• [11]Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. 2012.
• [12]Razaghi E. Evaluation of Afghanistan OST pilot project: final report. Eastern Mediterranean Regional Office: World Health Organization. 2011.
• [13]Bautista CT, Todd CS, Abed AM, Botros BA, Strathdee SA, Earhart KC et al.. Effects of duration of injection drug use and age at first injection on HCV among IDU in Kabul, Afghanistan. J Public Health (Oxf). 2010; 32(3):336-41.
• [14]Lin C, Wu Z, Detels R. Family support, quality of life and concurrent substance use among methadone maintenance therapy clients in China. Public Health. 2011; 125(5):269-274.
• [15]Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH et al.. Methadone dose, take home status, and hospital admission among methadone maintenance patients. J Addiction Med. 2012; 6(3):186-190.
• [16]Peles E, Schreiber S, Sason A, Adelson M. Earning "take-home" privileges and long-term outcome in a methadone maintenance treatment program. J Addiction Med. 2011; 5(2):92-98.
• [17]Guo S, Winslow M, Manning V, Thane KK. Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore. Ann Acad Med Singap. 2010; 39(6):429-434.
• [18]Drame FM, Peitzmeier S, Lopes M, Ndaw M, Sow A, Diouf D et al.. Gay men and other men who have sex with men in West Africa: evidence from the field. Cult Health Sex. 2013; 15 Suppl:7-21.
• [19]Amato L, Davoli MA, Perucci C, Ferri M, Faggiano FP, Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005; 28(4):321-329.
• [20]Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Library. 2004; 10:CD004145.
• [21]Tilson H, Aramrattana A, Bozzette S, Celentano D, Falco M, Hammett T et al.. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Institute of Medicine, Washington, DC; 2007.
• [22]Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend. 2001; 62(3):255-264.
• [23]Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R et al.. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010; 376(9737):268-284.